deoxyepinephrine has been researched along with Chronic Disease in 20 studies
Deoxyepinephrine: Sympathomimetic, vasoconstrictor agent.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study whether topical ibopamine effectively increases the intraocular pressure in patients with ocular hypotony after vitreoretinal surgery, uveitis, or penetrating trauma." | 9.12 | Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma. ( Cohen, AC; Ganteris, E; Jansen, J; Mulder, PG; Ugahary, LC; van Meurs, JC; Veckeneer, M, 2006) |
| "The purpose of this study was to determine the additive value of ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors." | 9.08 | Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. ( Girbes, AR; Kruik, J; Lie, KI; Szabó, BM; van der Burgh, PH; van Veldhuisen, DJ, 1996) |
| "Ibopamine, a dopamine derivative suitable for oral administration, is reported to improve cardiac function in patients with chronic heart failure." | 9.06 | Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. ( Alicandri, C; Boni, E; Fariello, R; Muiesan, G; Zaninelli, A, 1989) |
| "To evaluate the effectiveness of 6 months treatment with ibopamine eye drops in raising the intraocular pressure in patients with therapy-resistant hypotony after vitreoretinal surgery for proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment or penetrating trauma." | 7.78 | Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. ( Cohen, AF; Ganteris-Gerritsen, E; Jansen, J; Mulder, PG; Ugahary, LC; van Meurs, JC, 2012) |
| "Ibopamine 2 % eye drops in combination with topical steroids are a therapeutic option in uveitis-associated ocular hypotony." | 7.73 | [Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine]. ( Iliev, ME; Windisch, BK, 2006) |
| " To examine the influence of the oral dopamine agonist ibopamine on these factors, we studied 20 rats with chronic myocardial infarction and CHF, and compared them with 20 normal rats." | 7.69 | Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure. ( Buikema, H; de Graeff, PA; de Smet, BJ; Girbes, AR; Lie, KI; Scholtens, E; van Gilst, WH; van Veldhuisen, DJ; Wesseling, H, 1994) |
| "A group of 36 patients with cor pulmonale chronicum were treated for 12 months with ibopamine, a dopamine-related drug, orally active, suitable for the long-term therapy of congestive heart failure." | 7.67 | Treatment of heart failure following chronic cor pulmonale with ibopamine. ( Bianco, L; Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Sabino, F, 1988) |
| "50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition." | 7.67 | Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure. ( Avanzini, Z; Bellogini, GC; Brusoni, B; Ciampani, N; Dei Cas, L; Gazzola, U; Maggi, GC; Mangiavacchi, M; Metra, M; Pinca, L, 1986) |
| "Ibopamine was given alone to 39 patients; the others were given the drug in association with digitalis, diuretics, and vasodilators." | 6.66 | Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. ( Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Rolandi, E; Sabino, F, 1989) |
| "Ibopamine was then administered orally in single doses of 50 mg on day 2 and 100 mg on day 3." | 6.66 | Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. ( Castellaccio, M; Dore, L; Ibba, GV; Sannia, L, 1986) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 6.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| "Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study." | 5.28 | Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure. ( Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992) |
| "Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated." | 5.27 | Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. ( Dei Cas, L; Manca, C; Metra, M; Nodari, S; Riva, S; Visioli, O, 1988) |
| "To study whether topical ibopamine effectively increases the intraocular pressure in patients with ocular hypotony after vitreoretinal surgery, uveitis, or penetrating trauma." | 5.12 | Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma. ( Cohen, AC; Ganteris, E; Jansen, J; Mulder, PG; Ugahary, LC; van Meurs, JC; Veckeneer, M, 2006) |
| "The purpose of this study was to determine the additive value of ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors." | 5.08 | Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. ( Girbes, AR; Kruik, J; Lie, KI; Szabó, BM; van der Burgh, PH; van Veldhuisen, DJ, 1996) |
| "Ibopamine, a dopamine derivative suitable for oral administration, is reported to improve cardiac function in patients with chronic heart failure." | 5.06 | Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. ( Alicandri, C; Boni, E; Fariello, R; Muiesan, G; Zaninelli, A, 1989) |
| "To evaluate the effectiveness of 6 months treatment with ibopamine eye drops in raising the intraocular pressure in patients with therapy-resistant hypotony after vitreoretinal surgery for proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment or penetrating trauma." | 3.78 | Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. ( Cohen, AF; Ganteris-Gerritsen, E; Jansen, J; Mulder, PG; Ugahary, LC; van Meurs, JC, 2012) |
| "Ibopamine 2 % eye drops in combination with topical steroids are a therapeutic option in uveitis-associated ocular hypotony." | 3.73 | [Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine]. ( Iliev, ME; Windisch, BK, 2006) |
| " To examine the influence of the oral dopamine agonist ibopamine on these factors, we studied 20 rats with chronic myocardial infarction and CHF, and compared them with 20 normal rats." | 3.69 | Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure. ( Buikema, H; de Graeff, PA; de Smet, BJ; Girbes, AR; Lie, KI; Scholtens, E; van Gilst, WH; van Veldhuisen, DJ; Wesseling, H, 1994) |
| "A group of 36 patients with cor pulmonale chronicum were treated for 12 months with ibopamine, a dopamine-related drug, orally active, suitable for the long-term therapy of congestive heart failure." | 3.67 | Treatment of heart failure following chronic cor pulmonale with ibopamine. ( Bianco, L; Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Sabino, F, 1988) |
| "50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition." | 3.67 | Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure. ( Avanzini, Z; Bellogini, GC; Brusoni, B; Ciampani, N; Dei Cas, L; Gazzola, U; Maggi, GC; Mangiavacchi, M; Metra, M; Pinca, L, 1986) |
| "Ibopamine was given alone to 39 patients; the others were given the drug in association with digitalis, diuretics, and vasodilators." | 2.66 | Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial. ( Cantoni, V; Cicchetti, V; Ghirardi, P; Marchetti, GV; Rolandi, E; Sabino, F, 1989) |
| "Ibopamine was then administered orally in single doses of 50 mg on day 2 and 100 mg on day 3." | 2.66 | Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. ( Castellaccio, M; Dore, L; Ibba, GV; Sannia, L, 1986) |
| "Ibopamine treatment was ineffective in Group 2, while in Group 1 patients there was a statistically significant increase in creatinine clearance (+23% after 3 months, +31% after 6 months)." | 2.65 | Long-term treatment of chronic renal insufficiency with Ibopamine (SB 7505), a new orally active dopamine-related drug. ( Colí, L; Docci, D; Mosconi, G; Prandini, R; Stefoni, S; Vangelista, A, 1982) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 2.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| "Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study." | 1.28 | Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure. ( Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992) |
| "Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated." | 1.27 | Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure. ( Dei Cas, L; Manca, C; Metra, M; Nodari, S; Riva, S; Visioli, O, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (45.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganteris-Gerritsen, E | 1 |
| Ugahary, LC | 2 |
| Jansen, J | 2 |
| Mulder, PG | 2 |
| Cohen, AF | 1 |
| van Meurs, JC | 2 |
| Ganteris, E | 1 |
| Veckeneer, M | 1 |
| Cohen, AC | 1 |
| Windisch, BK | 1 |
| Iliev, ME | 1 |
| Stefoni, S | 1 |
| Docci, D | 1 |
| Vangelista, A | 1 |
| Mosconi, G | 1 |
| Colí, L | 1 |
| Prandini, R | 1 |
| Walsh, JT | 1 |
| Andrews, R | 1 |
| Evans, A | 1 |
| Cowley, AJ | 1 |
| van Veldhuisen, DJ | 5 |
| Brodde, OE | 1 |
| van Gilst, WH | 2 |
| Schulze, C | 1 |
| Hegeman, H | 1 |
| Anthonio, RL | 1 |
| Scholtens, E | 2 |
| de Graeff, PA | 2 |
| Wesseling, H | 2 |
| Lie, KI | 3 |
| de Smet, BJ | 1 |
| Buikema, H | 1 |
| Girbes, AR | 3 |
| Szabó, BM | 1 |
| van der Burgh, PH | 1 |
| Kruik, J | 1 |
| Niebauer, J | 1 |
| Coats, AJ | 1 |
| Hillege, HL | 1 |
| de Kam, PJ | 1 |
| Boomsma, F | 1 |
| de Zeeuw, D | 1 |
| Charlesworth, A | 1 |
| Hampton, JR | 1 |
| Itoh, H | 1 |
| Taniguchi, K | 1 |
| Tsujibayashi, T | 1 |
| Koike, A | 1 |
| Sato, Y | 1 |
| Nakamura, S | 1 |
| Alicandri, C | 1 |
| Fariello, R | 1 |
| Boni, E | 1 |
| Zaninelli, A | 1 |
| Muiesan, G | 1 |
| Rolandi, E | 1 |
| Sabino, F | 2 |
| Cantoni, V | 2 |
| Ghirardi, P | 2 |
| Marchetti, GV | 2 |
| Cicchetti, V | 2 |
| Hasenfuss, G | 1 |
| Just, H | 1 |
| Dei Cas, L | 2 |
| Metra, M | 2 |
| Nodari, S | 1 |
| Riva, S | 1 |
| Manca, C | 1 |
| Visioli, O | 1 |
| Bianco, L | 1 |
| Benassi, A | 1 |
| Modena, MG | 1 |
| Mattioli, G | 1 |
| Sannia, L | 1 |
| Ibba, GV | 1 |
| Castellaccio, M | 1 |
| Dore, L | 1 |
| Avanzini, Z | 1 |
| Bellogini, GC | 1 |
| Brusoni, B | 1 |
| Ciampani, N | 1 |
| Gazzola, U | 1 |
| Maggi, GC | 1 |
| Mangiavacchi, M | 1 |
| Pinca, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure[NCT02133105] | Phase 3 | 33 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deoxyepinephrine and Chronic Disease
| Article | Year |
|---|---|
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Chronic Disease; D | 1989 |
9 trials available for deoxyepinephrine and Chronic Disease
| Article | Year |
|---|---|
Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma.
Topics: Administration, Topical; Adult; Aged; Chronic Disease; Cross-Over Studies; Deoxyepinephrine; Dopamin | 2006 |
Long-term treatment of chronic renal insufficiency with Ibopamine (SB 7505), a new orally active dopamine-related drug.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Creatinine; Deoxyepine | 1982 |
Failure of "effective" treatment for heart failure to improve normal customary activity.
Topics: Activities of Daily Living; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disea | 1995 |
Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Blood Gas Ana | 1996 |
Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Cardiac Output; Cardiotonic Agents; Catecholamines; Ch | 2000 |
Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study.
Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Digoxin; Dopamine; Double-Blind | 1989 |
Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Dru | 1989 |
The efficacy of ibopamine in long-term treatment of dilated cardiomyopathy. A clinical and instrumental evaluation.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Deoxy | 1986 |
Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure.
Topics: Adult; Cardiac Output; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Heart Failur | 1986 |
10 other studies available for deoxyepinephrine and Chronic Disease
| Article | Year |
|---|---|
Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Deoxyepinephrine; Dopamine Agonists; Eye Injuries, | 2012 |
[Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine].
Topics: Administration, Topical; Chronic Disease; Deoxyepinephrine; Humans; Male; Mydriatics; Ocular Hypoten | 2006 |
Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Chronic Dise | 1995 |
Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Chronic Disease; Deoxyepinep | 1994 |
Treating chronic heart failure: time to take stock.
Topics: Chronic Disease; Deoxyepinephrine; Dopamine Agonists; Heart Failure; Humans; Randomized Controlled T | 1997 |
Treatment of mild heart failure: the place of diuretics and ibopamine.
Topics: Chronic Disease; Deoxyepinephrine; Diuretics; Dopamine Agonists; Drug Therapy, Combination; Heart Fa | 1997 |
Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure.
Topics: Administration, Oral; Aged; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dose-Response Rel | 1992 |
Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure.
Topics: Adult; Aged; Chronic Disease; Deoxyepinephrine; Drug Tolerance; Heart Failure; Humans; Male; Middle | 1988 |
Treatment of heart failure following chronic cor pulmonale with ibopamine.
Topics: Aged; Aged, 80 and over; Chronic Disease; Deoxyepinephrine; Diuretics; Dopamine; Dose-Response Relat | 1988 |
Monitored long-term treatment with ibopamine in patients suffering from severe congestive heart failure.
Topics: Adult; Aged; Body Weight; Cardiotonic Agents; Chronic Disease; Deoxyepinephrine; Dopamine; Female; H | 1986 |